TLSA vs. TRVI, ANAB, IMTX, DAWN, MRVI, AUTL, STOK, URGN, PHAT, and RLAY
Should you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Trevi Therapeutics (TRVI), AnaptysBio (ANAB), Immatics (IMTX), Day One Biopharmaceuticals (DAWN), Maravai LifeSciences (MRVI), Autolus Therapeutics (AUTL), Stoke Therapeutics (STOK), Urogen Pharma (URGN), Phathom Pharmaceuticals (PHAT), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry.
Tiziana Life Sciences vs. Its Competitors
Trevi Therapeutics (NASDAQ:TRVI) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.
In the previous week, Trevi Therapeutics had 7 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 8 mentions for Trevi Therapeutics and 1 mentions for Tiziana Life Sciences. Trevi Therapeutics' average media sentiment score of 0.50 beat Tiziana Life Sciences' score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the media.
Trevi Therapeutics presently has a consensus price target of $20.88, indicating a potential upside of 256.23%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Trevi Therapeutics is more favorable than Tiziana Life Sciences.
Trevi Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of -0.05, suggesting that its share price is 105% less volatile than the S&P 500.
95.8% of Trevi Therapeutics shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Tiziana Life Sciences' return on equity of 0.00% beat Trevi Therapeutics' return on equity.
Summary
Trevi Therapeutics beats Tiziana Life Sciences on 8 of the 12 factors compared between the two stocks.
Get Tiziana Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tiziana Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:TLSA) was last updated on 7/9/2025 by MarketBeat.com Staff
